A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8(+) T cell epitope, NY-ESO-1(88-96) (LEFYLAMPF) and compared its direct- and cross-presentation to th...

Full description

Bibliographic Details
Main Authors: Rona Y Zhao, Nicole A Mifsud, Kun Xiao, Kok-Fei Chan, Sara Oveissi, Heather M Jackson, Nektaria Dimopoulos, Philippe Guillaume, Ashley J Knights, Tamara Lowen, Neil C Robson, Sarah E Russell, Emmanuel Scotet, Ian D Davis, Eugene Maraskovsky, Jonathan Cebon, Immanuel F Luescher, Weisan Chen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3435279?pdf=render